# Regenxbio (RGNX) — Analyst Forecast

RGNX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rgnx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 2 | 0 | 12 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $12.00 | $21.00 | $29.00 | 4 |

Last price $7.16 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 5, 2026 | Mizuho | Initiated Coverage | Outperform | $22.00 |
| Aug 25, 2026 | Baird | Maintained | Outperform | $29.00 |
| Aug 25, 2026 | HC Wainwright & Co. | Maintained | Buy | $21.00 |
| Aug 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Aug 7, 2026 | Barclays | Downgraded | Overweight → Equal-Weight | $12.00 |
| Jun 24, 2026 | HC Wainwright & Co. | Maintained | Buy | $26.00 |
| Jun 22, 2026 | Leerink Partners | Maintained | Outperform | $18.00 |
| Jun 22, 2026 | Baird | Maintained | Outperform | $32.00 |
| Jun 5, 2026 | HC Wainwright & Co. | Maintained | Buy | $26.00 |
| May 15, 2026 | Barclays | Maintained | Overweight | $12.00 |
| May 15, 2026 | B of A Securities | Maintained | Buy | $14.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $30.00 |
| Mar 6, 2026 | Morgan Stanley | Maintained | Overweight | $17.00 |
| Feb 10, 2026 | Chardan Capital | Maintained | Buy | $50.00 |
| Feb 10, 2026 | Morgan Stanley | Maintained | Overweight | $18.00 |
| Feb 10, 2026 | Goldman Sachs | Maintained | Neutral | $12.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $32.00 |
| Jan 29, 2026 | Chardan Capital | Maintained | Buy | $52.00 |
| Dec 19, 2025 | Stifel | Maintained | Buy | $45.00 |
| Dec 15, 2025 | Leerink Partners | Maintained | Outperform | $20.00 |

## Frequently Asked Questions

### What is the price target for RGNX stock?

The average 12-month analyst price target for Regenxbio (RGNX) is $21.00, with a high estimate of $29.00 and a low of $12.00, across 4 analysts.

### Is RGNX a buy, sell, or hold?

Analysts covering Regenxbio currently average a Buy rating: 10 buy, 2 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for RGNX?

The average price target of $21.00 implies 193.30% upside from the last price of $7.16.

### What is the latest analyst rating on RGNX?

On Oct 5, 2026, Mizuho initiated coverage of Regenxbio at Outperform with a price target of $22.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).